Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LSBWF | 6-K | bullish | 7/10 | LakeShore Biopharma has called an Extraordinary General Meeting (EGM) for June 19, 2026, to vote on a previously announc | May 28, 2026 |
| PRFX | 6-K | neutral | 3/10 | PRF Technologies issued a press release announcing progress on its DeepSolar Predict AI-driven renewable energy revenue | May 28, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract accept | May 28, 2026 |
| DYAI | 8-K | neutral | 4/10 | Dyadic (DYAI) announced a research collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candi | May 28, 2026 |
| REX | 8-K | mixed | 5/10 | REX American Resources reported Q1 2026 results with net sales of $156.5M (slightly down YoY from $158.3M) but net incom | May 28, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for seve | May 28, 2026 |
| VIR | 8-K | neutral | 2/10 | Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to | May 28, 2026 |
| ENTX | PRESS-RELEASE | bullish | 6/10 | Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clin | May 28, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc announced that its majority-owned subsidiary NeuroThera received conditional TSX approval for the acquisition o | May 28, 2026 |
| MNKD | 8-K | bullish | 6/10 | MannKind announced the FDA released it from a postmarketing requirement for Afrezza, a five-year pulmonary malignancy st | May 28, 2026 |
| PLYX | PRESS-RELEASE | mixed | 6/10 | Polaryx Therapeutics closed a $10M PIPE financing at ~$4.00/share, issuing 2.5M new shares. Proceeds will fund the Phase | May 28, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma issued a voluntary announcement that its RSU trustee purchased 100,000 existing shares on-market for HK | May 28, 2026 |
| HOTH | 8-K | mixed | 5/10 | Rocket One Inc. (RKTO) filed an 8-K announcing two events: (1) an increase in its at-the-market (ATM) offering capacity | May 28, 2026 |
| BMRA | PRESS-RELEASE | bullish | 6/10 | Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assay | May 28, 2026 |
| ANRO | 8-K | neutral | 3/10 | Alto Neuroscience appointed Dr. Andrew Miller, founder of Karuna Therapeutics (acquired by Bristol Myers Squibb), to its | May 28, 2026 |
| PHGE | 8-K | neutral | 2/10 | BiomX Inc. appointed Roy Rousso as Chief Business Officer (and, per the consulting agreement, COO/CBO) effective July 1, | May 28, 2026 |
| ENLV | 6-K | bullish | 6/10 | Enlivex disclosed that its RAIN token holdings were valued at approximately $1.16 billion as of May 27, 2026, representi | May 28, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Pr | May 28, 2026 |
| SLGL | 6-K | mixed | 6/10 | Sol-Gel reported Q1 2026 revenue of $0.1M (down 89.5% YoY from $1.0M) and a net loss of $3.7M ($1.31/share), improved fr | May 28, 2026 |
| SLGL | PRESS-RELEASE | neutral | 5/10 | Revenue fell to $0.1M from $1.0M on a prior-year milestone payment. The company raised $33.1M in an oversubscribed offer | May 28, 2026 |
| BCDA | 8-K | bullish | 7/10 | BioCardia announced that Japan's PMDA Consultation Record supports submission for regulatory approval of CardiAMP cell t | May 28, 2026 |
| MEHA | 8-K | bearish | 6/10 | Functional Brands Inc. (MEHA) adjourned its Special Meeting of Stockholders due to insufficient shares present to form a | May 28, 2026 |
| IMRN | 6-K | neutral | 3/10 | Immuron filed a 6-K containing its response to an ASX price query regarding a sharp price spike from A$0.032 to A$0.044 | May 28, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a 6-K announcing it will ring the NYSE Closing Bell on May 29, 2026 to celebrate 25 years of its NYSE | May 28, 2026 |
| ZBIO | PRESS-RELEASE | bullish | 7/10 | Zenas BioPharma submitted a Biologics License Application (BLA) to the FDA for obexelimab in IgG4-RD, based on positive | May 28, 2026 |
| CHRS | DEFA14A | neutral | 4/10 | Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining votes on Proposal N | May 28, 2026 |
| GLAXF | 6-K | bullish | 7/10 | GSK announced positive pivotal Phase 3 data for bepirovirsen, achieving a 19% functional cure rate in chronic hepatitis | May 28, 2026 |
| SLNCF | EFFECT | bearish | 5/10 | Silence Therapeutics' $300M universal shelf registration (including a $100M ATM facility) became effective on May 27, 20 | May 28, 2026 |
| SLNO | EFFECT | bearish | 5/10 | Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared effective by the SEC on | May 28, 2026 |
| AIMD | CLUSTER | neutral | 2/10 | Ainos, Inc. (AIMD) insiders executed a mixed cluster of trades over a 7-day window ending May 22, 2026. Two directors so | May 27, 2026 |